Related Experiment Video
Updated: Aug 24, 2026

A Modified Method for Heterotopic Mouse Heart Transplantion
Published on: June 23, 2014
[Heart transplantation]
1Hjertemedisinsk avdeling, Rikshospitalet, 0027 Oslo. svein.simonsen@rikshospitalet.no
Insights
Heart transplantation in Nordic countries offers a viable treatment for select patients with end-stage heart failure. Strict selection criteria and post-transplant care are crucial for optimizing survival outcomes.
Area of Science:
- Cardiology
- Surgical Innovation
Background:
- Heart transplantation was first performed in the Nordic countries in 1983.
- It is now an accepted treatment for specific heart failure patients.
Purpose of the Study:
- To review heart transplantation practices at Rikshospitalet.
- To outline patient selection, outcomes, and challenges.
Main Methods:
- Review of heart transplantation cases at Rikshospitalet.
- Analysis of patient selection criteria, contraindications, and survival rates.
Main Results:
- Strict selection criteria are necessary due to donor shortage.
- One-year survival is 85%, and ten-year survival is 53%.
- Early mortality linked to rejection and infection; late mortality to coronary disease and cancer.
Conclusions:
- Heart transplantation is a critical treatment for carefully selected, end-stage heart failure patients.
- Patient motivation, cooperation, and strict adherence to medical advice are vital.
- Collaboration between referring physicians and the transplant center improves prognosis.
Abstract:
The first heart transplantation in the Nordic countries was performed at Rikshospitalet in Oslo, Norway in 1983 and the method is now accepted as a good treatment for selected patients. In this article we present a review of heart transplantation as it is practiced in our hospital. Because of donor shortage, the selection criteria are strict. It is most important that the patients are motivated and able to cooperate. They should be in heart failure class IV (III-IV) on the best medical treatment with no other treatment alternatives. Estimated survival without transplantation should be less than 6-12 months. Important contraindications are concurrent diseases with a more severe prognosis than that expected after transplantation. One-year and ten-year survival after transplantation at Rikshospitalet are 85% and 53%. The most important causes of death in the early postoperative period are rejection and infections. Later, the most frequent causes of death are accelerated coronary artery disease and cancer. Collaboration between the referring physician and the transplant centre is essential for a better prognosis for heart failure and after transplantation.
Related Concept Videos
Kidney Transplant I: Introduction
Cardiomyopathy V: Interprofessional Care
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

